2025.Sep.03

Corporate

OBI Pharma and AP Biosciences Sign Technology Collaboration Agreement to Develop Next-Generation ADC

OBI Pharma, Inc. (4174.TWO, “OBI”) today (09/03) announced that it has entered into a Material Transfer and Technology Development Agreement (MTA) to collaborate with AP Biosciences, Inc. (6945.TWO, “AP Biosciences”) on the development of a next-generation bispecific Antibody-Drug Conjugate (ADC).

HOMEWhat’s NewNewsOBI Pharma and AP Biosciences Sign Technology Collaboration Agreement to Develop Next-Generation ADC

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2025.Sep.01

OBI Pharma, Inc. Announces Board Resolution for Capital Reduction to Offset Accumulated Losses and Holds Material Information Press Conference